izpis_h1_title_alt

Co-crystals, salts or mixtures of both? The case of tenofovir alafenamide fumarates
ID Lengauer, Hannes (Author), ID Makuc, Damjan (Author), ID Šterk, Damjan (Author), ID Perdih, Franc (Author), ID Pichler, Arthur (Author), ID Trdan Lušin, Tina (Author), ID Plavec, Janez (Author), ID Časar, Zdenko (Author)

.pdfPDF - Presentation file, Download (3,70 MB)
MD5: 6C0109C8703ACBEF8083424FF92F68A4
URLURL - Source URL, Visit https://www.mdpi.com/1999-4923/12/4/342 This link opens in a new window

Abstract
Tenofovir alafenamide fumarate (TAF) is the newest prodrug of tenofovir that constitutes several drug products used for the treatment of HIV/AIDS. Although the solid-state properties of its predecessor tenofovir disoproxil fumarate have been investigated and described in the literature, there are no data in the scientific literature on the solid state properties of TAF. In our report, we describe the preparation of two novel polymorphs II and III of tenofovir alafenamide monofumarate (TA MF2 and TA MF3). The solid-state structure of these compounds was investigated in parallel to the previously known tenofovir alafenamide monofumarate form I (TA MF1) and tenofovir alafenamide hemifumarate (TA HF). Interestingly, the single-crystal X-ray diffraction of TA HF revealed that this derivative exists as a co-crystal form. In addition, we prepared a crystalline tenofovir alafenamide free base (TA) and its hydrochloride salt (TA HCl), which enabled us to determine the structure of TA MF derivatives using $^{15}$N-ssNMR ($^{15}$N-solid state nuclear magnetic resonance). Surprisingly, we observed that TA MF1 exists as a mixed ionization state complex or pure salt, while TA MF2 and TA MF3 can be obtained as pure co-crystal forms.

Language:English
Keywords:co-crystal, salt, polymorphism, X-ray diffraction, ssNMR, tenofovir alafenamide fumarate
Work type:Article
Typology:1.01 - Original Scientific Article
Organization:FKKT - Faculty of Chemistry and Chemical Technology
FFA - Faculty of Pharmacy
Publication status:Published
Publication version:Version of Record
Year:2020
Number of pages:21 str.
Numbering:Vol. 12, iss. 4, art. 342
PID:20.500.12556/RUL-133367 This link opens in a new window
UDC:615
ISSN on article:1999-4923
DOI:10.3390/pharmaceutics12040342 This link opens in a new window
COBISS.SI-ID:1569374 This link opens in a new window
Publication date in RUL:24.11.2021
Views:1281
Downloads:145
Metadata:XML DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:Pharmaceutics
Shortened title:Pharmaceutics
Publisher:MDPI
ISSN:1999-4923
COBISS.SI-ID:517949977 This link opens in a new window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:10.04.2020

Projects

Funder:Other - Other funder or multiple funders
Funding programme:Lek/Sandoz

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back